CEO Heather Turner told investors the company is positioned for a series of “clinically meaningful value creating catalysts” following its most recent financing, with multiple late-stage readouts plan ...

The AACE update to its 2026 algorithm for the management of type 2 diabetes includes a new section on diabetes classification.

The Phase III study FIND-CKD ( NCT05047263) — investigating the efficacy and safety of KERENDIA ® (finerenone) versus placebo when added to standard of care in adult patients with non-diabetic chronic ...

Curis, Inc. (NASDAQ:CRIS) Q4 2025 Earnings Call Transcript March 19, 2026 Curis, Inc. misses on earnings expectations. Reported EPS is $-0.5 EPS, expectations were $-0.436. Operator: Good afternoon, ...

Flathead County Commissioners approved a new set of septic regulations and construction standards that specifically allows for the installation of gravity-fed septic systems. Since 2004, the county ...

New analyses show DLB patients with lower plasma pTau181 levels — indicating an earlier stage of disease and absence of Alzheimer’s disease (AD) ...

Thank you, and welcome to Curis' Fourth Quarter 2025 Business Update Call. Before we begin, I'd like to encourage ...

According to Maximize Market Research, the Global Heparin Market is projected to reach USD 8.7 billion in 2025 and is expected to grow at a CAGR of 4.57% from 2026 to 2032. The market is witnessing ...

Detailed price information for Southern Silver Exploration Corp. (SSV-X) from The Globe and Mail including charting and ...

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that it has selected ASC39, a potent and amylin-selective oral small molecule amylin receptor agonist, as a clinical development candidate.

Detailed price information for Eton Pharmaceutcials Inc (ETON-Q) from The Globe and Mail including charting and trades.

The bispecific T-cell engager talquetamab (Talvey) has some distinct adverse events (AEs) compared with drugs of the same class that target B-cell maturation antigen (BCMA) in mul ...